| 苏健民,谭云龙,周东丰,曹连元,杨甫德,邹义壮,张向阳,张培琰.迟发性运动障碍与SODVal9Ala多态性的关系及柴胡桃仁胶囊治疗其疗效观察[J].中国中西医结合杂志,2007,(8):700-703 |
| 迟发性运动障碍与SODVal9Ala多态性的关系及柴胡桃仁胶囊治疗其疗效观察 |
| Relationship between Tardive Dyskinesia and the Polymorphism of Superoxide Dismutase Val9Ala and Efficacy of Chaihu Taoren Capsules on It |
| 免费下载全文 查看/发表评论 下载PDF阅读器 |
| |
| DOI： |
| 中文关键词: 运动障碍 药源性 精神分裂症 超氧化物歧化酶 多态性 |
| 英文关键词:dyskinesia drug-induced schizophrenia superoxide dismutase polymorphism |
| 基金项目:首都医学发展科研基金(No.2002-3095);北京中医药管理局基金(No.JJ2001-11) |
|
| 摘要点击次数: 1320 |
| 全文下载次数: 1 |
| 中文摘要: |
| 目的探讨迟发性运动障碍(tardive dyskinesia,TD)与超氧化物歧化酶(superoxide dismutase,SOD)第9位密码子从缬氨酸到丙氨酸的错义突变(Val9Ala,T1183C)多态性关系及柴胡桃仁胶囊治疗TD的疗效。方法应用异常不自主运动量表(abnormal involuntary movement scale,AI MS)评定TD严重程度,阳性和阴性症状量表(positive and negative symptoms scale,PANSS)评定患者精神症状。将入组TD患者119例(TD组),与TD患者一般状况严格相匹配慢性精神分裂症患者129例(非TD组),健康人148名(正常组),应用聚合酶链反应-限制性片段长度多态性方法分析TD组、非TD组及正常组Val9Ala基因分布频率,并观察柴胡桃仁胶囊治疗TD患者36例12周的疗效。结果正常组、TD组和非TD组在SOD Val9Ala基因型上差异无显著性(P>0.05);在等位基因分布频率上差异无显著性(P>0.05);对不同基因型的TD患者的AI MS总分进行了比较,基因型为TT与CT的患者AI MS总分间差异无显著性(P>0.05);柴胡桃仁胶囊对CT杂合子疗效显著优于TT纯合子(P<0.05)。结论柴胡桃仁胶囊能有效缓解TD症状,疗效可能与SOD的基因型有关;9Ala可能是TD发生的保护因素。 |
| 英文摘要: |
| Objective To investigate the relationship between efficacy of Chaihu Taoren Decoction (CTD) and the polymorphism of valine-alanine missense mutation of 9th codan (Val9Ala, T1183C) of superoxide dismutase (SOD) in patients with tardive dyskinesia (TD). Methods Severity of TD was assessed by abnormal involuntary movement scale (AIMS), and the psychologic symptoms were rated by the positive and negative symptoms scale (PANSS). The sample size consisted of 119 patients with TD assigned to the TD group, 129 patients of chronic schizophrenia with the general condition matched strictly with that of the enrolled TD patients assigned to the non-TD group, and 148 healthy persons assigned to the normal group. The gene distribution rate of Val9Ala gene was analyzed using polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) analysis, and the therapeutic effect of CTD on 36 patients with TD was observed after 12 weeks treatment. Results There was no significant difference in genotype and allelic gene frequency of SOD Val9Ala among the TD, non-TD and normal groups (P>0.05). Comparison of the AIMS score in TD patients with various Val9Ala genotypes showed that the difference of AIMS scores in patients with TT and CT genotype was not significant (P>0.05), but CTD did show a better efficacy in TD patients with CT heterozygote than in those with TT homozygote (P<0.05). Conclusion The CTD could effectively relieve the symptoms of TD, its efficacy might be related with the genotype of SOD, and 9Ala is considered to be a protective factor for the susceptibility to TD. |
| 关闭 |
|
|
|
扫描微信二维码，获取更多信息